By Ed Ballard
LONDON--AstraZeneca PLC (AZN.LN) Monday said European regulators
have approved Duaklir Genuair, an inhaler treatment for chronic
obstructive pulmonary disease.
The European Commission cleared the drug for use by adults after
studies of its effects on more than 2,000 patients in 11 clinical
studies demonstrated that it improved lung function compared to
competitor drugs, AstraZeneca said.
"AstraZeneca owns the rights to develop and commercialize
Duaklir Genuair in the European Union following the strategic
business combination of Almirall's respiratory portfolio, which was
completed last month," the Anglo-Swedish drug company said.
"The E.U. approval of Duaklir Genuair marks an important further
step in AstraZeneca's inhaled-therapy strategy of providing
physicians and patients a choice of products uniquely available in
both dry powder and pressurised metered dose devices," it said.
Write to Ed Ballard at ed.ballard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires